CarpoNovum AB (“CarpoNovum” or the “Company”), a Swedish medical technology company specializing in innovative surgical instruments for colorectal surgery and CE-approved products, has recently completed a private placement of shares amounting to approximately SEK 23 million (the "Private Placement"). With continued strong support from major shareholders such as Carl Bennet AB, Anders Walldov, and Denis Viet Jacobsen, the Company can accelerate its clinical validation and reach key regulatory milestones in 2025. Corpura acted as financial advisor in connection with the Private Placement.
CarpoNovum has developed C-REX®, a new generation of surgical instruments designed to minimize leakage in colorectal anastomoses. The Company’s mission is to improve patients’ quality of life following colorectal cancer surgery by offering innovative solutions that replace traditional methods such as stapling and suturing. The proceeds from the share issue will be used to:
• Execute an ongoing multicenter study in Europe in close collaboration with Amsterdam University Medical Center, with the goal of further validating previous clinical results
• Accelerate the process of obtaining FDA 510(k) clearance in 2025
• Enable strategic pre-commercial activities
CarpoNovum is an award-winning medical technology company dedicated to minimizing leakage in colorectal anastomoses. The Company offers a new generation of surgical instruments for colorectal surgery with its C-REX® system, aimed at improving patients’ quality of life after colorectal cancer surgery. The C-REX® portfolio is CE-approved with the right to be commercialized in Europe, and the Company has also submitted an application for FDA clearance in the U.S. via 510(k).
Corpura Fondkommission acted as financial advisor in connection with the Private Placement.
For more information contact:
Jonatan Andersson
Phone: +46 (0)70-508 00 51
Email: jonatan.andersson@corpura.se
